elearning

Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Bookmark and Share

Biomarkers for selection of IOI

This module focuses on the discovery of biomarkers of efficacy prediction, biomarkers of interest and their importance for the future of immunotherapy.

This e-learning course is comprised of 15 modules providing an up-to-date resource for medical professionals who seek to understand the latest research, advances in technology and future directions of immune-oncology. Developed by ecancer in collaboration with King’s College London aimed at medical professionals interested in the field of immuno-oncology.

Published February 2019.

Biomarkers for selection of IOI
Module
English
0 CME Points

Target audience

This module is aimed at medical professionals interested in the field of immuno-oncology.

Learning objectives

By the end of this module you will be able to:

  • Describe the challenges facing biomarker discovery
  • Describe the emerging biomarkers for CTLA-4 and PD-1/PD-L1
  • Understand the scope of research in novel technologies that are emerging
  • Describe the key factors of patient education for immune-oncology

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Disclosure policy

ecancer and everyone involved in the development of this module has no actual or potential conflict of interest whatsoever which impinges on the making, peer reviewing and dissemination of this e-learning module which was made possible through an unrestricted educational grant from the Bristol-Myers Squibb Foundation and AbbVie Inc.

Both the BMS Foundation and AbbVie Inc. have had no input in the creation of the e-learning materials including the process of selecting speakers.

For more information, please email education@ecancer.org

Support

Production of this module was funded by an unrestricted grant from The Bristol-Myers Squibb Foundation and AbbVie Inc.